NCT03837704View on ClinicalTrials.gov

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

April 6, 2023

Study Completion Date

August 28, 2023

Conditions
SmokingAbdominal Aortic AneurysmIQOS Use
Interventions
OTHER

IQOS

AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.

OTHER

Cigarette

AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.

OTHER

Smoking Cessation

AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)

Trial Locations (13)

270-2251

Chiba-Nishi General Hospital, Matsudo

279-0001

Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu

969-1793

Fujita General Hospital, Fujita

377-0061

Kitakanto Cardiology Hospital, Shizukawa

247-8533

Shonan Kamakura General Hospital, Okamoto

243-8588

Atsugi City Hospital, Atsugi

210-0822

AOI Universal Hospital, Kawasaki

215-0026

Shin-Yurigaoka General Hospital, Kawasaki

360-0197

Saitama Cardiovascular and Respiratory Center, Itai

596-8522

Kishiwada Tokushukai Hospital, Kishiwada

344-0063

Kasukabe Chuo General Hospital, Kasukabe

992-0472

Okitama Public General Hospital, Nanyō

536-0025

Omichikai Morinomiya Hospital, Osaka

All Listed Sponsors
lead

Philip Morris Products S.A.

INDUSTRY

NCT03837704 - Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. | Biotech Hunter | Biotech Hunter